GliaCure Highlighted in ADDF Annual Report
GliaCure’s compound GC021109 and its successful Phase 1 clinical trial were highlighted in the Alzheimer’s Drug Discovery Foundation (ADDF) Annual Report, issued in late 2017. The report points out that there is growing research to suggest that anti-inflammatory approaches may hold the key to treating the underlying causes of Alzheimer’s disease, and shows that GC021109...more »